Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-25-003744
Filing Date
2025-02-13
Accepted
2025-02-13 15:41:04
Documents
58
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q inbp20241231_10q.htm   iXBRL 10-Q 1071694
2 EXHIBIT 31.1 CERTIFICATION OF CO-CEOS ex_771540.htm EX-31.1 13555
3 EXHIBIT 31.2 CERTIFICATION OF CFO ex_771541.htm EX-31.2 15165
4 EXHIBIT 32.1 CERTIFICATION OF CO-CEOS PURSUANT TO SECTION 302 ex_771542.htm EX-32.1 9119
5 EXHIBIT 32.2 CERTIFICATION OF CFO PURSUANT SECTION 302 ex_771543.htm EX-32.2 7189
  Complete submission text file 0001437749-25-003744.txt   5359811

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA inbp-20241231.xsd EX-101.SCH 42581
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE inbp-20241231_cal.xml EX-101.CAL 32663
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE inbp-20241231_def.xml EX-101.DEF 292775
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE inbp-20241231_lab.xml EX-101.LAB 252709
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inbp-20241231_pre.xml EX-101.PRE 316103
61 EXTRACTED XBRL INSTANCE DOCUMENT inbp20241231_10q_htm.xml XML 961948
Mailing Address 225 LONG AVENUE BUILDING 15 HILLSIDE NJ 07205
Business Address 225 LONG AVENUE BUILDING 15 HILLSIDE NJ 07205 9739260816
INTEGRATED BIOPHARMA INC (Filer) CIK: 0001016504 (see all company filings)

EIN.: 222407475 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-31668 | Film No.: 25619843
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)